Akums Drugs & Pharmaceuticals Ltd, a leading Indian CDMO, posted solid financial performance for Q3 FY26, recording 14.8% revenue growth and a 21% year-on-year rise in adjusted EBITDA to ₹147 crore. The CDMO segment registered over 16% revenue growth driven by higher volumes, while the international branded formulations business more than doubled sequentially due to improved demand in key markets. Improved capacity utilization and ramp-up of new facilities supported margin expansion. Cost discipline and portfolio optimization helped reduce losses in API and trade generics operations.
The company strengthened its global footprint by securing European Union Good Manufacturing Practice certification for two facilities, including renewal for its Oral Solids plant and new certification for its Oral Liquids plant. It also received its first approval from the UK MHRA for Rivaroxaban tablets.
Management highlighted continued focus on compliant infrastructure, operational excellence, and disciplined global expansion across regulated markets. Akums Drugs & Pharmaceuticals Ltd. is one of India’s largest Contract Development and Manufacturing Organizations (CDMO). The company specializes in manufacturing pharmaceutical formulations and providing end-to-end development services for domestic and international clients.
Akums operates multiple manufacturing facilities across India, producing a wide range of dosage forms including tablets, capsules, injectables, syrups, and topical formulations. It serves both branded and generic pharmaceutical markets, supplying products to leading pharmaceutical companies.
The company places strong emphasis on regulatory compliance and quality assurance, holding certifications from global regulatory authorities such as the EU GMP and UK MHRA. Its infrastructure supports research, formulation development, packaging, and large-scale manufacturing.
Akums continues to expand its presence in regulated international markets while strengthening operational efficiency and capacity utilization. Through investments in modern manufacturing technologies, skilled workforce development, and global quality standards, the company is positioning itself as a competitive global pharmaceutical manufacturing partner. With a focus on disciplined growth and innovation, Akums contributes significantly to India’s pharmaceutical manufacturing ecosystem and export capabilities.
